Adaptimmune Therapeutics Announces Sale of Key Cell Therapies to US WorldMeds in Strategic Move

Reuters

2025/07/28

Adaptimmune <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Sale of Key Cell Therapies to US WorldMeds in Strategic Move

Adaptimmune Therapeutics plc has announced a definitive agreement to sell its TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to US WorldMeds. The sale is expected to be completed by the end of the week. As part of the transaction, US employees involved in the development and commercialization of these therapies will be offered employment with US WorldMeds to ensure continuity. Adaptimmune plans to restructure to support US WorldMeds in the ongoing development of these therapies, while focusing on maximizing value from its remaining assets, including its PRAME and CD70 directed T-cell therapies. The transaction will be financed by debt financing led by Oaktree Capital Management, L.P., with participation from Athyrium Capital Management, LP. US WorldMeds' CEO, Breck Jones, emphasized the company's commitment to advancing these therapies, while Adrian Rawcliffe, CEO of Adaptimmune, highlighted the strategic importance of this transaction for the company and its stakeholders.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptimmune Therapeutics plc published the original content used to generate this news brief via Newsfile (Ref. ID: 260248) on July 28, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2554776684"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2554776684\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2554776684?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-28 19:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2554776684","market":"nz","top_or_hot":-1,"title":"Adaptimmune Therapeutics Announces Sale of Key Cell Therapies to US WorldMeds in Strategic Move","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Adaptimmune <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Sale of Key Cell Therapies to US WorldMeds in Strategic Move\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ADAP\">Adaptimmune Therapeutics plc</a> has announced a definitive agreement to sell its TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to US WorldMeds. The sale is expected to be completed by the end of the week. As part of the transaction, US employees involved in the development and commercialization of these therapies will be offered employment with US WorldMeds to ensure continuity. Adaptimmune plans to restructure to support US WorldMeds in the ongoing development of these therapies, while focusing on maximizing value from its remaining assets, including its PRAME and CD70 directed T-cell therapies. The transaction will be financed by debt financing led by Oaktree Capital Management, L.P., with participation from Athyrium Capital Management, LP. US WorldMeds' CEO, Breck Jones, emphasized the company's commitment to advancing these therapies, while Adrian Rawcliffe, CEO of Adaptimmune, highlighted the strategic importance of this transaction for the company and its stakeholders.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptimmune Therapeutics plc published the original content used to generate this news brief via Newsfile (Ref. ID: 260248) on July 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adaptimmune Therapeutics Announces Sale of Key Cell Therapies to US WorldMeds in Strategic Move</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdaptimmune Therapeutics Announces Sale of Key Cell Therapies to US WorldMeds in Strategic Move\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-28 19:31</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Adaptimmune <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Sale of Key Cell Therapies to US WorldMeds in Strategic Move\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ADAP\">Adaptimmune Therapeutics plc</a> has announced a definitive agreement to sell its TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to US WorldMeds. The sale is expected to be completed by the end of the week. As part of the transaction, US employees involved in the development and commercialization of these therapies will be offered employment with US WorldMeds to ensure continuity. Adaptimmune plans to restructure to support US WorldMeds in the ongoing development of these therapies, while focusing on maximizing value from its remaining assets, including its PRAME and CD70 directed T-cell therapies. The transaction will be financed by debt financing led by Oaktree Capital Management, L.P., with participation from Athyrium Capital Management, LP. US WorldMeds' CEO, Breck Jones, emphasized the company's commitment to advancing these therapies, while Adrian Rawcliffe, CEO of Adaptimmune, highlighted the strategic importance of this transaction for the company and its stakeholders.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptimmune Therapeutics plc published the original content used to generate this news brief via Newsfile (Ref. ID: 260248) on July 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nNDL44mkPC:1","article_id":"2554776684","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2554776684","pubTimestamp":1753702266,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Adaptimmune Therapeutics plc has announced a definitive agreement to sell its TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to US WorldMeds. The sale is expected to be completed by the end of the week. As part of the transaction, US employees involved in the development and commercialization of these therapies will be offered employment with US WorldMeds to ensure continuity. Adaptimmune plans to restructure to support US WorldMeds in the ongoing development of these therapies, while focusing on maximizing value from its remaining assets, including its PRAME and CD70 directed T-cell therapies. The transaction will be financed by debt financing led by Oaktree Capital Management, L.P., with participation from Athyrium Capital Management, LP. US WorldMeds' CEO, Breck Jones, emphasized the company's commitment to advancing these therapies, while Adrian Rawcliffe, CEO of Adaptimmune, highlighted the strategic importance of this transaction for the company and its stakeholders.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4007":"制药","SUPN":"Supernus Pharmaceuticals"},"translate_title":"Adaptimmune Therapeutics宣布战略举措向美国WorldMeds出售关键细胞疗法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADAP":0.9,"SUPN":0.9},"content_text":"Adaptimmune Therapeutics Announces Sale of Key Cell Therapies to US WorldMeds in Strategic Move\n    \n\nAdaptimmune Therapeutics plc has announced a definitive agreement to sell its TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to US WorldMeds. The sale is expected to be completed by the end of the week. As part of the transaction, US employees involved in the development and commercialization of these therapies will be offered employment with US WorldMeds to ensure continuity. Adaptimmune plans to restructure to support US WorldMeds in the ongoing development of these therapies, while focusing on maximizing value from its remaining assets, including its PRAME and CD70 directed T-cell therapies. The transaction will be financed by debt financing led by Oaktree Capital Management, L.P., with participation from Athyrium Capital Management, LP. US WorldMeds' CEO, Breck Jones, emphasized the company's commitment to advancing these therapies, while Adrian Rawcliffe, CEO of Adaptimmune, highlighted the strategic importance of this transaction for the company and its stakeholders.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptimmune Therapeutics plc published the original content used to generate this news brief via Newsfile (Ref. ID: 260248) on July 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}